CTI Clinical Trial & Consulting (CTI), a global, privately held, full‑service clinical research organization, today announced leadership promotions that position the company for its next phase of growth, innovation, and global impact. Jonathan Koch has been promoted to Chief Executive Officer (CEO) and Brian Lawrence has been promoted to Chief Financial Officer (CFO) & President. Founder Tim Schroeder will continue as Executive Chairman.  

“As the founder of a multi-generational business, succession planning and business continuity are paramount to the ongoing success of the organization,” said Schroeder. “I am incredibly proud and excited to announce the promotions of Jon and Brian. They are both high integrity, compassionate servant leaders who believe in the mission of CTI to support innovative research to patients and families with unmet healthcare needs.”  

These leadership changes reflect a deliberate, future‑focused succession strategy that builds on CTI’s strong foundation while enabling continued evolution to meet the needs of sponsors navigating increasingly complex clinical research. By elevating proven internal leaders, CTI reinforces its commitment to continuity, disciplined execution, and long‑term value creation.  

Jonathan Koch Promoted to Chief Executive Officer  

As CEO, Koch is driving CTI’s strategic vision, sharpening delivery excellence, strengthening operational rigor, and enabling scalable growth. He will also join the CTI Board of Directors, providing strategic continuity and long-term oversight. Since joining CTI at the beginning of 2025 as Chief Operating Officer and President, Koch has unified global operations, aligned teams and platforms, and prioritized leadership development and organizational growth—building the talent and infrastructure needed to accelerate execution and advance high-quality research across therapeutic areas.  

“CTI is a special organization because of its people and the trust our sponsors place in us,” said Koch. “What truly differentiates CTI is how our teams bring together clinical, laboratory, and site capabilities—combining deep operational expertise with exceptional scientific and therapeutic knowhow, particularly in advanced and complex therapies. I’ve had the privilege of working closely with our teams around the world, and as we move forward, my focus is on strengthening that foundation: supporting our people, optimizing how we deliver, and continuing to help bring important therapies to patients.”  

Brian Lawrence Promoted to Chief Financial Officer & President  

As CFO & President, Lawrence is steering CTI’s financial strategy while shaping enterprise priorities that enable sustainable, long‑term growth. Since joining CTI in 2014, he has progressed through senior finance leadership roles, including Vice President, Global Finance and Chief Financial Officer, driving major growth initiatives, strengthening financial discipline, and supporting operational expansion across the organization.  

“With more than a decade of my career at CTI, I’ve seen how a long-term perspective has guided the company’s success,” said Lawrence. “As we continue to grow, my priority is to ensure we’re making thoughtful decisions—investing in our people and capabilities while maintaining the discipline that allows us to serve our clients consistently and well.” 

Tim Schroeder Remains at CTI as Executive Chairman  

Founder Tim Schroeder will remain actively engaged as Executive Chairman, supporting Koch and Lawrence in their expanded roles while continuing to work closely with the Board of Directors, clients, and on key strategic initiatives. His transition reflects a planned evolution of leadership that ensures stability while empowering the next generation of leaders.